Anticancer effects and mechanisms of polysaccharide-K (PSK): Implications of cancer immunotherapy

Anticancer Research

Volumn 22, Issue 3, 2002, Pages 1737-1754

  Fisher, Monte ^a   Yang, Li Xi ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

Biological response modifier (BRM); Cancer; Immunotherapy; Krestin; Polysaccharide K (PSK)

Indexed keywords

ASBESTOS; BIOLOGICAL RESPONSE MODIFIER; CYTOKINE; KRESTIN; METALLOPROTEINASE; POLYSACCHARIDE; POLYSACCHAROPEPTIDE; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; COLORECTAL CANCER; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; ESOPHAGUS CANCER; HUMAN; IMMUNOSTIMULATION; LEUKEMIA CELL; LUNG CANCER; LYMPHOKINE ACTIVATED KILLER CELL; NATURAL KILLER CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; SECOND CANCER; STOMACH CANCER; TOBACCO;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; IMMUNOTHERAPY; PROTEOGLYCANS;

EID: 0036327261     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (174)

1. Immunomodulation of cancer: Potential use of selectively replicating agents
2. Effect of PSK on the recovery of macrophage function in tumor-bearing mice
3. Effects of PSK on resistance to bacterial infection in splenectomized mice
4. PSK and OK-432-induced immunomodulation of inducible nitric oxide (NO) synthase gene expression in mouse peritoneal polymorphonuclear leukocytes and NO-mediated cytotoxicity
5. Local treatment of locally recurrent breast cancers
6. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer
7. Inhibition of mouse sarcoma 180 by polysaccharides from Lentinus edodes (Berk.) sing
8. Effects of Ganoderma lucidum and krestin on cellular immunocompetence in gamma-ray-irradiated mice
9. Effects of Ganoderma lucidum and krestin on subset T-cell in spleen of gamma-irradiated mice
10. PSK immunotherapy in cancer patients-a preliminary report
11. Antitumor effect of PSK at a distant site: Inductions of interleukin-8-like factor and macrophage chemotactic factor in murine tumor
12. Antitumor effect of intratumoral administration of a Coriolus preparation, PSK: Inhibition of tumor invasion in vitro
13. Manganese superoxide dismutaseplasmid/liposome (MnSOD-PL) administration protects mice from esophagitis associated with fractionated radiation
14. Increased radiosensitivity of normal tissue fibroblasts in patients with acquired immunodeficiency syndrome (AIDS) and with Kaposi's sarcoma
15. Effects of krestin (PSK) on drug-metabolizing enzymes with special reference to the activation of FT-207
16. Effect of PSK, a protein-bound polysaccharide from Coriolus versicolor, on drug-metabolizing enzymes in sarcoma-180 bearing and normal mice
17. A clinical trial of cis-platinum (II) in combination with PSK and FT-207 in advanced stomach cancer
18. Induction in the mouse of gene expression of immunomodulating cytokines by mushroom polysaccharide-protein complexes
19. Protein-bound polysaccharide K and interleukin-2 regulate different nuclear transcription factors in the NKL human natural killer cell line
20. Adjuvant PSK immunotherapy in patients with carcinoma of the nasopharynx
21. Polysaccharide K induces Mn superoxide dismutase (Mn-SOD) in tumor tissues and inhibits malignant progression of QR-32 tumor cells: Possible roles of interferon alpha, tumor necrosis factor alpha and transforming growth factor beta in Mn-SOD induction by polysaccharide K
22. Induction of manganese superoxide dismutase by an immunopotentiator as a mechanism of inhibiting malignant progression of murine tumor cells
23. The effect of protein-bound polysaccharide (PSK) on lymphocyte subsets of peripheral venous blood and thoracic duct lymph
24. A case of bilateral renal cell carcinoma
25. Disappearance of lung metastases from hepatocellular carcinoma following PSK administration
26. Antitumor activities and tumor necrosis factor producibility of traditional Chinese medicines and crude drugs
27. Role of first stimulating agents in the production of tumor necrosis factor
28. Inhibition of mitomycin-C-induced sister-chromatid exchanges in mouse bone marrow cells by the immunopotentiators krestin and lentinan
29. Post-operative long-term adjuvant immunochemotherapy with mitomycin-C, PSK, and FT-207 in gastric cancer patients
30. Effect of krestin (PSK) as adjuvant treatment on the prognosis after radical radiotherapy in patients with non-small cell lung cancer
31. Enhancing effect of irradiation on carcinoma of the uterine cervix by administering the protein-bound polysaccharide kureha (PSK)-quantitative nuclear DNA analysis following irradiation
32. Primary transitional cell carcinoma of the male urethra: Report of a case
33. Immunohistochemical study of spleens in gastric cancer
34. Case report of a large endometrial stromal sarcoma
35. A biological response modifier, PSK, inhibits reverse transcriptase in vitro
36. Cloning of sequences induced and suppressed by administration of PSK, antitumor protein-bound polysaccharide
37. Histological analysis of lymphocyte subsets infiltrated into mouse tumor tissue exposed to local irradiation
38. Cell growth and gene modulatory activities of Yunzhi (Windsor Wunxi) from mushroom Trametes versicolor in androgen-dependent and androgen-insensitive human prostate cancer cells
39. Radiosensitivity in AIDS patients
40. Clinical results of a randomized controlled trial on the effect of adjuvant immunochemotherapy using esquinon and krestin in patients with curatively resected gastric cancer-7-year survival
41. A cooperative study of alternating immunochemotherapy with futraful and PSK (second report)-3-year survival rate
42. Plant polysaccharide PSK: Cytostatic effects on growth and invasion; modulating effect on the expression of HLA and adhesion molecules on human gastric and colonic tumor cell surface
43. Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer
44. Evaluation of postoperative immunochemotherapy in lung cancer
45. Fate and distribution of an antitumor protein-bound polysaccharide PSK (krestin)
46. Radiotherapy, bleomycin, and immunotherapy (PSK, BCG-CWS) in esophageal neoplasms
47. Direct tumor growth suppressive effect of melanoidin extracted from immunomodulator PSK
48. Morphological and biochemical alterations of macrophages produced by a glycan, PSK
49. Comparison of immunochemotherapy and chemotherapy of Stage IV gastric carcinoma
50. Late results of postoperative long-term cancer chemotherapy for the gastric cancer patients subjected to curative resection
51. Suppression of in vivo tumor-induced angiogenesis by the protein-bound polysaccharide PSK
52. Enhancement of the antitumor effect by the concurrent use of a monoclonal antibody and the protein-bound polysaccharide PSK in mice bearing a human cancer cell line
53. Mimicking of superoxide dismutase activity by protein-bound polysaccharide of Coriolus versicolor QUEL, and oxidative stress relief for cancer patients
54. Activation of human natural killer cells by the protein-bound polysaccharide PSK independently of interferon and interleukin-2
55. A suppressive effect of PSK, a protein-bound polysaccharide preparation, on tumor growth: A new effect of PSK on cell motility
56. Effect of recombinant human granulocyte colonystimulating factor (rhG-CSF) on cytotoxicity of PSK-induced peritoneal polymorphonuclear leukocytes (PMNs)
57. Effect of a protein-bound polysaccharide PSK on the complement system
58. Changes in serum soluble IL-2 receptors (sIL-2R) and immunosuppressive acidic protein (IAP) associated with chemotherapy for lung cancer
59. Effects of biological response modifiers on childhood ALL being in remission after chemotherapy
60. A case of recurrent hepatocellular carcinoma successfully treated by arterial chemoembolization in combination with local hyperthermia
61. The use of mushroom glucans and proteoglycans in cancer treatment
62. Effects of cimetidine and PSK on interleukin-2 production by PBL in patients with advanced ovarian carcinoma during the course of chemotherapy
63. Effects of PSK on interleukin-2 production by peripheral lymphocytes of patients with advanced ovarian carcinoma during chemotherapy
64. Stimulation of interferon-gamma-induced human myelogenous leukemic cell differentiation by high molecular weight PSK subfraction
65. In vitro chemopreventive effects of plant polysaccharides (Aloe barbadensis Miller, Lentinus edodes, Ganoderma lucidum and Coriolus versicolor)
66. Results in oligodendroglioma: Postoperative radiotherapy combined with chemotherapy
67. Results of supratentorial low-grade astrocytoma-effects of combined radiochemotherapy
68. Effect of PSK on interferon production in tumor-bearing mice
69. PSK as a chemopreventive agent
70. Antimetastatic effects of PSK (krestin), a protein-bound polysaccharide obtained from basidomycetes: An overview
71. Enhancement of anti-cancer activity of cisdiaminedichloroplatinum by the protein-bound polysaccharide of Coriolus versicolor QUEL (PSK) in vitro
72. Suppression of cancer cell growth in vitro by the protein-bound polysaccharide of coriolus versicolor QUEL (PSK) with SOD mimicking activity
73. Suppressive effects on cancer cell proliferation of the enhancement of superoxide dismutase (SOD) activity associated with the protein-bound polysaccharide of Coriolus versicolor QUEL
74. Improved recovery of myelosuppression following chemotherapy in mice by combined administration of PSK and various cytokines
75. Identification of a mouse serum protein increased by administration of an antitumor polysaccharide, PSK, as a variant of mouse transferrin and some of its biological activities
76. Evaluation of immunochemotherapy in patients with primary liver cancer
77. Successful treatment with tegafur and PSK in a patient with gallbladder cancer
78. A case report of successful immunochemotherapy of metastatic renal cell carcinoma using UFT and PSK
79. Suppressive effects of two biological response modifiers, krestin and levamisole, on 5-azacytidine-induced digital defects in rats
80. Reversal of inhibition of reactive oxygen species on respiratory burst of macrophages by polysaccharide from Coriolus versicolor
81. Immune enhancement of a polysaccharide peptide isolated from Coriolus versicolor
82. Adjuvant chemotherapy enhances long-term survival of patients with advanced gastric cancer following curative resection
83. Hippocratic screening of sixty-six species of higher fungi
84. The effects of PSK, a biological response modifier, on congenital ocular abnormalities induced by X-irradiation
85. Direct action of a protein-bound polysaccharide, PSK, on transforming growth factor-beta
86. Neonantal inoculation with the protein-bound polysaccharide PSK increases resistance of adult animals to challenge with syngeneic tumor cells and reduces azoxymethane-induced precancerous lesions in the colon
87. Restoration of depressed immune responses by PSK in C3H/He mice bearing syngeneic X5563 tumor
88. Competitive effect of PSK against the immunosuppressive effect induced in the sera of mice bearing syngeneic tumors
89. Restoration of immunological responsiveness by PSK in tumor-bearing animals
90. Antimetastatic effect of PSK, a protein-bound polysaccharide, against the BL16-BL6 mouse melanoma
91. A four-year follow-up study of hepatocellular carcinoma with bone metastasis
92. Immunotherapy for colorectal cancer
93. The effect of a protein-bound polysaccharide from Coriolus versicolor on immunological parameters and experimental infections in mice
94. Study of abscopal effect and cellular infiltration of tumor nests using less-fractionated, large-dose radiation
95. Clinical study of PSK as an adjuvant immunochemotherapeutic agent against gastric cancer
96. Randomized controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal
97. Combination therapy of radiation and immunomodulators in the treatment of MM46 tumor transplanted in C3H/He mice
98. A case of remission in metastatic lung tumor from hepatocellular carcinoma after combined CDDP and PSK therapy
99. Chemical structure of antitumor polysaccharide, coriolan, produced by Coriolus versicolor
100. In vitro inactivation of herpes simplex virus by a biological response modifier, PSK
101. Specific regulation of HSPs in human tumor cell lines by PSK
102. Evaluation of multidisciplinary treatment of bladder cancer, especially in chemoimmunotherapy (ADM and OK-432) as a consolidation therapy
103. Effects of a protein-bound polysaccharide from a basidiomycetes against hepatocarcinogenesis induced by 3′-methyl-4-dimethylaminoazo-benzene in rats
104. A multi-institutional study on postoperative adjuvant immunochemotherapy of gastric cancer
105. Multi-institutional cooperative study of adjuvant immunochemotherapy in gastric cancer-five-year survival rate
106. Clinical results of a randomized controlled trial on the effect of adjuvant immunochemotherapy using esquinon and krestin in patients with curatively resected gastric cancer
107. An effect of adjuvant immunochemotherapy using krestin and 5-FU on gastric cancer patients with radical surgery (first report) - A randomized controlled trial by the cooperative study group
108. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer
109. A review of research on the protein-bound polysaccharide (polysaccharopeptide, PSP) from the mushroom Coriolus versicolor (basidomycetes: polyporaceae)
110. Comparative biological and antitoxoplasmic effects of particulate and water-soluble polysaccharides, in vitro
111. Postoperative adjuvant immunochemotherapy with mitomycin C, futraful, and PSK for gastric cancer. An analysis of data on 579 patients followed for five years
112. Improvement of treatment of carcinoma of the thoracic esophagus, especially in reference to the transition in postoperative combined therapy
113. Progress in postoperative care and postoperative combined therapy of esophageal carcinoma by total parenteral nutrition (TPN)
114. A randomized controlled study of PSK combined immunochemotherapy for adenocarcinoma of the lung
115. Changes in nonspecific factors in the serum of gastric cancer patients after surgery and immunochemotherapy
116. Surgical stress and lymphocyte function: Effects of PSK to prevent cellular immunosuppression
117. Clinical effect of concomitant use of PSK on 121 cases of primary lung cancer (Stage III, IV) treated with radiation combined with chemotherapy
118. Immunotherapy and combined assay of serum levels of carcinoembryonic antigen and acute-phase reactants
119. Possible predictive markers of immunotherapy in esophageal cancer: Retrospective analysis of a randomized study
120. Evaluation of immunotherapy with PSK in esophageal cancer
121. Effect of PSK on cytotoxicity against sarcoma-180 in tumor-bearing mice
122. A randomized trial of chemoimmunotherapy of acute nonlymphocytic leukemia in adults using a protein-bound polysaccharide preparation
123. Immunomodulation and anticancer activity of polysaccharide-protein complexes
124. Biological response modifiers (BRM) as antigens: III. T cell lines specific for BRM kill tumor cells in a BRM-specific manner
125. Effect of polysaccharide krestin on glutathione peroxidase gene expression in mouse peritoneal macrophages
126. Polysaccharide krestin enhances manganese superoxide dismutase activity and mRNA expression in mouse peritoneal macrophages
127. An alternative explanation for the radiosensitization of AIDS patients
128. Soluble polyglycans enhance recovery from cobalt-60-induced hemopoietic injury
129. Study on postoperative local chemotherapy of malignant brain tumors using ACNU and PSK
130. Long-term survival of patients with brain tumors treated with ACNU and PSK after surgery-with special reference to their immunological follow-up
131. A study on postoperative long-term continuous immunochemotherapy with PSK and 5-FUDS for advanced gastric and colorectal cancers
132. Stimulation of tumor necrosis factor-induced human myelogenous leukemic cell differentiation by high molecular weight PSK subfraction
133. Induction of immunopotentiation activity by a protein-bound polysaccharide, PSK
134. Effect of a biological response modifier, PSK, on intestinal flora of tumor-bearing mice
135. Filgrastim (r-metHuG-CSF) and its potential use in the reduction of radiation-induced oropharyngeal mucositis: An interim look at a randomized, double-blind, placebo-controlled trial
136. Two cases of unresectable pancreatic cancer responding to combined chemotherapy with cisplatin, PSK, and UFT
137. Effectiveness of multidisciplinary treatment combined with immunotherapy in esophageal cancer-analysis of 287 cases of carcinoma of the thoracic part of the esophagus in Kyushu and Yamaguchi districts
138. Combined radio-immuno-chemotherapy for medulloblastoma
139. Clinical studies on PSK: Combination therapy of PSK with radiation in cancer of the uterine cervix
140. Nonspecific cell-mediated immunity of gynecologic cancer patients and related effects of chemotherapy and immunotherapy
141. Case of hepatocellular carcinoma with a marked reduction in the tumor size induced by PSK administration alone
142. Effect of PSK on prostaglandin metabolism
143. Clinical effect of postoperative adjuvant immunochemotherapy with FT-207 suppository and PSK in colorectal patients
144. A multi-institutional study on postoperative adjuvant immunochemotherapy of gastric cancer (II)
145. Depression of protective mechanisms against ectromelia virus infection in tumor-bearing mice and its prevention by PSK
146. A biological response modifier, PSK, inhibits human immunodeficiency virus infection in vitro
147. Antiviral agents with activity against human retroviruses
148. Surgical stress and immunosuppression in cancer patients
149. The effect and distribution of a protein-bound polysaccharide preparation, PSK (krestin), intratumorally injected prior to surgery into gastric cancer patients
150. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer
151. Effect of a protein-bound polysaccharide, PSK, on human hemopoietic progenitors
152. Treatment of tumors of the urinary bladder with so-called immunopotentiators
153. Krestin (PSK)
154. Depression of macrophage functions and T-cell-mediated immunity to listeria infection in tumor-bearing mice and its prevention by PSK
155. Effect of PSK on tumor-specific immunity induced by MMC-treated syngeneic tumor cells
156. Involution of the thymus in tumor-bearing mice and its restoration by PSK
157. Effects of combined therapies with protein-bound polysaccharide (PSK, krestin) and fluorinated pyrimidine derivatives on experimental liver metastases and on the immunologic capacities of the hosts
158. Effect of PSK on the recovery of macrophage function and T-cell-mediated immunity in tumor-bearing mice
159. Depression of early protection against influenza virus infection by cyclophosphamide and its restoration by protein-bound polysaccharide
160. Protective effect of PSK, a protein-bound polysaccharide preparation against candidiasis in tumor-bearing mice
161. Leukocyte migration inhibition (LMI) of murine spleen cells after immunization with tumor cells, and an experimental study with LMI in combination therapy with a non-specific immunostimulant and chemotherapeutic agent
162. Expression of manganese superoxide dismutase reduces tumor control radiation dose: Gene-radiotherapy
163. Glutathione deficiency and radiosensitivity in AIDS patients
164. AUFRAP therapy: Combined modality treatment of malignant gliomas with intraarterial infusion of ACNU
165. Therapeutic effects of substances occurring in higher basidomycetes mushrooms: A modern perspective
166. A long-term survivor of primary hepatoma-a case suggesting the superiority of a multi-drug (OK-432, SPG, PSK) over mono-drug therapy
167. Direct antitumor activity of biological response modifiers (BRM) proven by an in vitro sensitivity test
168. Surgery and adjuvant therapy of cancer of the large intestine
169. Prophylactic intervention in radiation-leukemia-virus-induced murine lymphoma by the biological response modifier polysaccharide K
170. HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy with PSK
171. Enhancement of antitumor cytotoxicity of hepatic lymphocytes by oral administration of PSK
172. Protein-bound polysaccharide PSK inhibits tumor invasiveness by down-regulation of TGF-β-1 and MMPs
173. The effect of tert-butyl hydroperoxide on peritoneal macrophages and the protective effect of protein-bound polysaccharide administered intraperitoneally and orally
174. Reduction of the oxidative injury to the rabbits with established atherosclerosis by protein bound polysaccharide from Coriolus versicolor